Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F19%3A00505825" target="_blank" >RIV/61388971:_____/19:00505825 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/19:10394374 RIV/00064203:_____/19:10394374
Result on the web
<a href="https://www.frontiersin.org/articles/10.3389/fimmu.2019.00967/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fimmu.2019.00967/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fimmu.2019.00967" target="_blank" >10.3389/fimmu.2019.00967</a>
Alternative languages
Result language
angličtina
Original language name
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
Original language description
Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific vs. unspecific approaches, doses of tolDCs and/or autoantigens, application schemes, application routes, the migration of tolDCs as well as their preventive, early pre-onset intervention or curative effects. This review also discusses perspectives of tolDC therapy and areas of preclinical research that are in need of better clarification in animal models in a quest for effective and optimal tolDC therapies of T1D in humans.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
<a href="/en/project/NV16-27994A" target="_blank" >NV16-27994A: The effect of gluten-free diet on residual beta cell capacity, immune functions and gut microbiome in children with newly diagnosed type 1 diabetes</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Immunology
ISSN
1664-3224
e-ISSN
—
Volume of the periodical
10
Issue of the periodical within the volume
MAY 14
Country of publishing house
CH - SWITZERLAND
Number of pages
14
Pages from-to
967
UT code for WoS article
000467844100001
EID of the result in the Scopus database
2-s2.0-85067271405